Trials / Recruiting
RecruitingNCT05761366
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
Detailed description
Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors (including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Al18F-PSMA-BCH PET/CT | Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan. |
Timeline
- Start date
- 2022-10-13
- Primary completion
- 2025-10-13
- Completion
- 2025-10-13
- First posted
- 2023-03-09
- Last updated
- 2024-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05761366. Inclusion in this directory is not an endorsement.